Novo Nordisk A/S is recruiting a Principal ADME Scientist for its Development ADME department in Maloev, near Copenhagen. The role suits an experienced ADME (absorption, distribution, metabolism, excretion) scientist with drug-drug interaction (DDI) expertise who wants a permanent, senior position in a global pharmaceutical R&D organization.
The role
- Evaluate ADME and DDI risks and strategy from late-stage discovery through non-clinical and clinical development to regulatory submission
- Design, conduct and interpret in vitro and in vivo studies across modalities (small molecules, peptides and biologics), in-house and with contract research organisations
- Provide written input to regulatory documents such as IB, IND, IMPD, BLA and NDA
- Champion new scientific initiatives by reviewing literature and technological advances in the field
- Communicate complex scientific data and recommendations to stakeholders with varied scientific backgrounds
Requirements
- PhD preferred, or a master’s degree in pharmaceutical or medical sciences or an equivalent field
- Several years of relevant experience in ADME, ideally including DDI, in pharmaceutical or biotech drug development
- Solid experience with bioanalytical and mass spectrometric methods for characterizing and quantifying drug candidates and metabolites
- Demonstrated ability to interpret and translate results from in vitro, ex vivo and in vivo ADME and DDI studies
- Experience with due diligence evaluation within ADME and DDI is an advantage
About the employer
Novo Nordisk is a global Danish healthcare company known for its work in diabetes and obesity care, with more than 100 years of history in pharmaceutical research and development.
Salary and deadline
The annual base salary ranges from DKK 742,600 to 1,091,600, with the exact level set during recruitment based on the candidate’s skills and experience; short- and long-term incentives and other benefits may also apply. Application deadline: 27/09/2026. The ad does not state which specific point in the range a given candidate would receive before the process concludes.
Source: Novo Nordisk A/S, “Principal ADME Scientist”, read 11 September 2026. Summary by AVIDE; see the original page for the full and current text.